After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved …

Despite remarkable advances over the past several decades, many therapeutic
nanomaterials fail to overcome major in vivo delivery barriers. Controlling immunogenicity …

Despite the vast diversity of the antibody repertoire, infected individuals often mount
antibody responses to precisely the same epitopes within antigens. The immunological …

Heterologous prime-boost immunization strategies have the potential to augment COVID-19
vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 …

The RSVPreF3-AS01 vaccine, containing the respiratory syncytial virus (RSV) prefusion F
protein and the AS01 adjuvant, was previously shown to boost neutralization responses …

Unrelated individuals can produce genetically similar clones of antibodies, known as public
clonotypes, which have been seen in responses to different infectious diseases, as well as …

There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess
the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc …

Antibodies are key proteins of the adaptive immune system, and there exists a large body of
academic literature and patents dedicated to their study and concomitant conversion into …

Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …

T cells are integral components of the adaptive immune system, and their responses are
mediated by unique T-cell receptors (TCR) that recognize specific antigens from a variety of …